Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis

Yeo, Brian Sheng Yep; Song, Harris Jun Jie Muhammad Danial; Soong, Yoke Lim; Chua, Melvin Lee Kiang; Ang, Mei‐Kim; Lim, Diane S. W.; See, Anna; Lim, Chwee Ming

doi:10.1016/j.oraloncology.2022.106242

Cited by 5 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[22][23][24] Although the fact that there have been meta-analyses investigating the safety and efficacy of PD-1 inhibitors in patients with nasopharyngeal carcinoma, the main studies included in these meta-analyses were non-RCTs. 25,26 In addition, to date, no comparative studies have been conducted to assess the relative efficacy and safety of different PD-1 inhibitors in treating recurrent or metastatic nasopharyngeal carcinoma. Thus, we performed the network meta-analysis.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials

Sun,

Bu,

et al. 2023

Ann Pharmacother

View full text Add to dashboard Cite

Background Different clinical trials for recurrent or metastatic nasopharyngeal carcinoma have studied different combinations of immuno-oncology in first-line treatment, but the optimal choice has not been determined. Objective To systematically examine and compare the efficacy and safety of different immune checkpoint inhibitors (ICIs) combined with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. Methods Several electronic databases were systematically searched up to February 2023. Articles meeting the inclusion criteria were included. Results Three RCTs were eligible in the study. Compared with placebo plus gemcitabine-cisplatin (GP), toripalimab plus GP (HR = 0.59, 95% CI: 0.37-0.95) was significantly associated with a better OS. Tislelizumab plus GP generated best progression-free survival (PFS) benefit (HR = 0.50, 95% CI: 0.37-0.67), greatest improvement in 1-year PFS rate (RR = 3.00, 95% CI: 1.84-5.22), and objective response rate (ORR) (RR = 1.26, 95% CI: 1.04-1.53) over the placebo plus GP. Furthermore, tislelizumab plus GP appeared to be safer than toripalimab plus GP and camrelizumab plus GP in terms of adverse events (AEs)-grade ≥3, treatment-related AEs (TRAEs)-grade ≥3, serious AEs (SAEs), treatment-related SAEs (TRSAEs), and AEs leading to discontinuation of treatment. Conclusion and Relevance In recurrent or metastatic nasopharyngeal carcinoma, programmed death 1 (PD-1) inhibitors plus GP as first-line treatment have better survival outcomes than placebo plus GP with comparable toxicity. Toripalimab plus GP shows the best OS benefit over placebo plus GP, while tislelizumab plus GP generates the best PFS, 1-year PFS rate, ORR, and safety. Tislelizumab plus GP could be the best choice among the ICIs combined with chemotherapy regimens as first-line treatment in recurrent or metastatic nasopharyngeal carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials

Sun,

Bu,

et al. 2023

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…However, no other studies in Other immune therapies are increasingly reported, mainly in adult NPC, but also in pediatric NPC, including the use of immune checkpoint inhibitors (ICI) and EBVspecific T cells, both showing promising responses, although these are mainly used in the setting of progressive or relapsed disease. [62][63][64][65][66][67][68][69][70]…”

Section: Maintenance Therapymentioning

confidence: 99%

“…Anti-PD1 monotherapy 63,64,66 ORR 21-34 Anti-PD1+chemotherapy 63,64,66 ORR 68-73 EBV-CTLs+chemotherapy 78 10 y OS 44 Pazopanib monotherapy 79 PR 6 Axitinib 80 PR 19 Anti-EGFR+chemotherapy 81 ORR 71 Toripalimab+chemotherapy 70 ORR 78.8…”

Section: Therapymentioning

confidence: 99%

Nasopharyngeal Carcinoma in Children, Current Treatment Approach

Ben-Ami

2024

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is a rare and locally aggressive form of childhood cancer. Treatment of pediatric NPC includes chemotherapy and radiotherapy. Most studies on the treatment of pediatric NPC are single-arm studies. With current treatment protocols survival rates for patients with nonmetastatic disease exceed 80%, although most children will have long-term treatment-related late effects. Efforts to reduce early and late toxicities include reduced radiotherapy doses in children with good responses to induction chemotherapy. Further studies are needed to evaluate the role of immunotherapy in both the primary setting and in children with progressive or relapsed disease. This review summarizes current clinical approaches to the treatment of pediatric NPC.

show abstract

Comment on: Efficacy of Anti-PD1 blockade in treating recurrent or metastatic nasopharyngeal cancer: A systematic review and meta-analysis

Zhang

Liao

2023

Oral Oncology

View full text Add to dashboard Cite

Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis

Cited by 5 publications

References 44 publications

Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials

Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials

Nasopharyngeal Carcinoma in Children, Current Treatment Approach

Comment on: Efficacy of Anti-PD1 blockade in treating recurrent or metastatic nasopharyngeal cancer: A systematic review and meta-analysis

Contact Info

Product

Resources

About